Search

Displaying results 2741 - 2750 of 10000 in total
  1. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    the accompanying vial of AS01E adjuvant as the adjuvant suspension component. … [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States

  2. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. … [A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.

  3. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

  4. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].

    Synonyms: L-5-MTHF, (6S)-5-MTHFMixtures: Medi-10, L-Methyl MC
  5. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  6. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  7. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    BA.4, BA.5) which, although similar, may behave differently from one another.[L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]

    Mixtures: Comirnaty Original/omicron Ba.1
  8. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  9. Drug

    MK-0773

    go.drugbank.com/drugs/DB16244
    Investigational

    MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).

  10. Drug

    MK-8666

    go.drugbank.com/drugs/DB14937
    Investigational

    MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).